[ad_1]
PARIS (awp / afp) – The pharmaceutical industry is expecting a lot from the next Strategic Council of Health Industries (Csis) which will meet Tuesday at Matignon, demanding a "change of software" from the top of the state to restore colors to their sector and restore confidence
Created in 2004 and meeting every two years under the aegis of the Prime Minister, the Csis is a forum for dialogue between the state and the health industries (drugs, technologies and medical devices)
It will be preceded this year of a dinner Monday at the Elysee between Emmanuel Macron and thirty leaders of French and international pharmaceutical groups.
"The involvement of the Elysee in the construction of the Csis is a new element, it gives more weight "to the event, greets Patrick Errard, president of Leem, the French federation of drug manufacturers, interviewed by AFP.
" It seems to be on a This is concrete measures, with a follow-up, rather than intentionalities "without much effect in previous editions, he adds.
" But it is here and now that it happens, or not before a good time (…). If the impulse is not powerful enough, one may fear that the continuation is not coherent with our expectations ", he warns.
.
" Chronic evil "
The industries of health constitute a heavyweight of the French economy: the federation of the sector, the Féfis, gathers more than 2,500 companies of all sizes, totaling a turnover of 90 billion euros and representing 455,000 direct and badociated jobs. the country's third largest export sector, behind the aeronautics and the automobile industry
But the industry has been feeling ill for several years, hit hard by price cuts and strict controls on the rise in drug expenditure.
The share of the drug contributed in 2017 to 43% of the savings realized in the framework of the national objective of the expenses of health insurance (Ondam), whereas it represented only 16,6 % of these expenses ales, against more than 51% for the hospital, says the Leem.
"To this is added a chronic evil: a hallucinating administrative complexity" hindering the establishment of clinical trials in France, collaborations with public research institutes, and greatly lengthening the time required for the marketing authorization of medicinal products, denounces Mr Errard
"This is not without impact on attractiveness, competitiveness, our ability to invest and the possibility that the pharmaceutical industry based in France could radiate "abroad," he adds.
The specific turnover of reimbursable medicines in France fell by an average of 0.6% over the period 2013-2017, and French drug exports fell by 3.7% last year, according to Leem.
Remuneration "fair"
To these difficulties is added the bad reputation of the manufacturers of the drug, particularly pregnant France since the health scandal of the Mediator, and more recently with the recurrent controversies over the prices of therapeutic innovations
"But it is not because there was the Mediator that one must be banished from the public stage for 30 years "indignant Emmanuelle Quilès, CEO of Janssen France, biopharmaceutical subsidiary of the American giant Johnson and Johnson.
" And it is not because we make money with the drug that one is responsible for original sin. To create, to innovate, it is necessary to invest "and that deserves a" fair "remuneration, adds Mrs. Quilès, besides candidate to the succession of Mr. Errard at the head of the Leem in September (with Philippe Tcheng, head of the governmental relations to Sanofi).
The prices of new drugs capable of treating previously incurable diseases should also be evaluated in terms of the savings they generate for the community, for example by reducing the number of hospitalizations and follow-ups of chronic patients.
"We must not be ashamed of this industry", summarizes the leader. "Mr. Macron speaks only of innovation, but the + tech +, it is in health that it also happens" with biotechnologies, she adds, admitting that Csis is not going to focus on digital and connected health to the detriment of the other components of the sector
etb / tq / LyS
Source link
